Arcus Biosciences Price to Free Cash Flow Ratio 2017-2023 | RCUS
Historical price to free cash flow ratio values for Arcus Biosciences (RCUS) since 2017.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Arcus Biosciences Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2023-06-02 |
21.01 |
|
0.00 |
| 2023-03-31 |
18.24 |
$-4.53 |
0.00 |
| 2022-12-31 |
20.68 |
$6.00 |
3.45 |
| 2022-09-30 |
26.16 |
$6.16 |
4.25 |
| 2022-06-30 |
25.34 |
$6.48 |
3.91 |
| 2022-03-31 |
31.56 |
$6.38 |
4.95 |
| 2021-12-31 |
40.47 |
$-3.81 |
0.00 |
| 2021-09-30 |
34.87 |
$-3.50 |
0.00 |
| 2021-06-30 |
27.46 |
$0.97 |
28.41 |
| 2021-03-31 |
28.08 |
$1.64 |
17.13 |
| 2020-12-31 |
25.96 |
$1.97 |
13.17 |
| 2020-09-30 |
17.14 |
$2.22 |
7.71 |
| 2020-06-30 |
24.74 |
$-2.00 |
0.00 |
| 2020-03-31 |
13.88 |
$-2.03 |
0.00 |
| 2019-12-31 |
10.10 |
$-1.72 |
0.00 |
| 2019-09-30 |
9.10 |
$-1.93 |
0.00 |
| 2019-06-30 |
7.95 |
$-1.59 |
0.00 |
| 2019-03-31 |
12.49 |
$-0.24 |
0.00 |
| 2018-12-31 |
10.77 |
$-1.35 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.484B |
$0.112B |
|
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
|
